[go: up one dir, main page]

WO2013052550A3 - Nouveaux modulateurs du système immunitaire à base d'imidazole quinoline - Google Patents

Nouveaux modulateurs du système immunitaire à base d'imidazole quinoline Download PDF

Info

Publication number
WO2013052550A3
WO2013052550A3 PCT/US2012/058566 US2012058566W WO2013052550A3 WO 2013052550 A3 WO2013052550 A3 WO 2013052550A3 US 2012058566 W US2012058566 W US 2012058566W WO 2013052550 A3 WO2013052550 A3 WO 2013052550A3
Authority
WO
WIPO (PCT)
Prior art keywords
immune system
based immune
imidazole quinoline
novel imidazole
system modulators
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2012/058566
Other languages
English (en)
Other versions
WO2013052550A2 (fr
Inventor
Grayson B. Lipford
Charles M. Zepp
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Janus Biotherapeutics Inc
Original Assignee
Janus Biotherapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janus Biotherapeutics Inc filed Critical Janus Biotherapeutics Inc
Priority to US14/349,254 priority Critical patent/US9873694B2/en
Priority to EP12837804.9A priority patent/EP2763677B1/fr
Priority to CA2850932A priority patent/CA2850932A1/fr
Priority to JP2014534658A priority patent/JP2014528449A/ja
Priority to AU2012318694A priority patent/AU2012318694B2/en
Priority to IN948KON2014 priority patent/IN2014KN00948A/en
Publication of WO2013052550A2 publication Critical patent/WO2013052550A2/fr
Anticipated expiration legal-status Critical
Priority to IL231957A priority patent/IL231957A0/en
Publication of WO2013052550A3 publication Critical patent/WO2013052550A3/fr
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Dermatology (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Emergency Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Obesity (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

La présente invention concerne un composé de formule I : ou un énantiomère, un diastéréomère, un tautomère de ce dernier, ou un sel ou un solvate pharmaceutiquement acceptable de ce dernier, dont les symboles sont définis dans la description. L'invention porte également sur une composition pharmaceutique le comprenant, et sur une méthode de traitement ou de prévention d'une maladie auto-immunitaire au moyen de ce dernier.
PCT/US2012/058566 2011-10-04 2012-10-03 Nouveaux modulateurs du système immunitaire à base d'imidazole quinoline Ceased WO2013052550A2 (fr)

Priority Applications (7)

Application Number Priority Date Filing Date Title
US14/349,254 US9873694B2 (en) 2011-10-04 2012-10-03 Imidazole quinoline-based immune system modulators
EP12837804.9A EP2763677B1 (fr) 2011-10-04 2012-10-03 Nouveaux modulateurs du système immunitaire à base d'imidazole quinoline
CA2850932A CA2850932A1 (fr) 2011-10-04 2012-10-03 Nouveaux modulateurs du systeme immunitaire a base d'imidazole quinoline
JP2014534658A JP2014528449A (ja) 2011-10-04 2012-10-03 新規なイミダゾールキノリン系免疫系調節剤
AU2012318694A AU2012318694B2 (en) 2011-10-04 2012-10-03 Novel imidazole quinoline-based immune system modulators
IN948KON2014 IN2014KN00948A (fr) 2011-10-04 2012-10-03
IL231957A IL231957A0 (en) 2011-10-04 2014-04-06 New immune system modulators based on imidazole quinoline

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161543082P 2011-10-04 2011-10-04
US61/543,082 2011-10-04

Publications (2)

Publication Number Publication Date
WO2013052550A2 WO2013052550A2 (fr) 2013-04-11
WO2013052550A3 true WO2013052550A3 (fr) 2014-05-15

Family

ID=48044383

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2012/058566 Ceased WO2013052550A2 (fr) 2011-10-04 2012-10-03 Nouveaux modulateurs du système immunitaire à base d'imidazole quinoline

Country Status (8)

Country Link
US (1) US9873694B2 (fr)
EP (1) EP2763677B1 (fr)
JP (1) JP2014528449A (fr)
AU (1) AU2012318694B2 (fr)
CA (1) CA2850932A1 (fr)
IL (1) IL231957A0 (fr)
IN (1) IN2014KN00948A (fr)
WO (1) WO2013052550A2 (fr)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9227969B2 (en) 2013-08-14 2016-01-05 Novartis Ag Compounds and compositions as inhibitors of MEK
US10071079B2 (en) 2016-06-29 2018-09-11 Bristol-Myers Squibb Company [1,2,4]triazolo[1,5-a]pyridinyl substituted indole compounds
WO2018026620A1 (fr) 2016-07-30 2018-02-08 Bristol-Myers Squibb Company Composés d'indole substitués par du diméthoxyphényle comme des inhibiteurs de tlr7, tlr8 ou tlr9
WO2018049089A1 (fr) 2016-09-09 2018-03-15 Bristol-Myers Squibb Company Composés indole substitués par pyridyle
WO2019028301A1 (fr) 2017-08-04 2019-02-07 Bristol-Myers Squibb Company Composés d'indole substitués par [1,2,4]triazolo[4,3-a] pyridinyle
WO2019028302A1 (fr) 2017-08-04 2019-02-07 Bristol-Myers Squibb Company Composés indole substitués utiles en tant qu'inhibiteurs de tlr7/8/9
EP3710440B1 (fr) 2017-11-14 2023-04-05 Bristol-Myers Squibb Company Composés d'indole substitués
CN111527080B (zh) 2017-12-15 2023-09-22 百时美施贵宝公司 取代的吲哚醚化合物
BR112020011771A2 (pt) 2017-12-18 2020-11-17 Bristol-Myers Squibb Company compostos 4-azaindol
AU2018390543A1 (en) 2017-12-19 2020-08-06 Bristol-Myers Squibb Company 6-azaindole compounds
US11878975B2 (en) 2017-12-19 2024-01-23 Bristol-Myers Squibb Company Substituted indole compounds useful as TLR inhibitors
ES2922174T3 (es) 2017-12-19 2022-09-09 Bristol Myers Squibb Co Compuestos de indol sustituidos con amida útiles como inhibidores de TLR
SG11202005694RA (en) 2017-12-20 2020-07-29 Bristol Myers Squibb Co Amino indole compounds useful as tlr inhibitors
EA202091530A1 (ru) 2017-12-20 2020-09-14 Бристол-Маерс Сквибб Компани Диазаиндольные соединения
MX2020005622A (es) 2017-12-20 2020-08-20 Bristol Myers Squibb Co Compuestos de indol sustituidos con arilo y heteroarilo.
US11998537B2 (en) 2018-10-24 2024-06-04 Bristol-Myers Squibb Company Substituted indole dimer compounds
JP7597709B2 (ja) 2018-10-24 2024-12-10 ブリストル－マイヤーズ スクイブ カンパニー 置換インドールおよびインダゾール化合物
CN113811299A (zh) * 2019-03-15 2021-12-17 博笛生物科技有限公司 用于治疗癌症的免疫调控性组合物和方法
JP7621275B2 (ja) 2019-05-09 2025-01-24 ブリストル－マイヤーズ スクイブ カンパニー 置換ベンズイミダゾロン化合物
EP4041730A1 (fr) 2019-10-01 2022-08-17 Bristol-Myers Squibb Company Composés hétéroaryle bicycliques substitués
JP7545467B2 (ja) 2019-10-04 2024-09-04 ブリストル－マイヤーズ スクイブ カンパニー 置換カルバゾール化合物
US11530218B2 (en) 2020-01-20 2022-12-20 Incyte Corporation Spiro compounds as inhibitors of KRAS
US11739102B2 (en) 2020-05-13 2023-08-29 Incyte Corporation Fused pyrimidine compounds as KRAS inhibitors
US11999752B2 (en) 2020-08-28 2024-06-04 Incyte Corporation Vinyl imidazole compounds as inhibitors of KRAS
US11767320B2 (en) 2020-10-02 2023-09-26 Incyte Corporation Bicyclic dione compounds as inhibitors of KRAS
WO2022204112A1 (fr) 2021-03-22 2022-09-29 Incyte Corporation Inhibiteurs d'imidazole et triazole kras
AU2022257039A1 (en) 2021-04-16 2023-10-05 Gilead Sciences, Inc. Thienopyrrole compounds
US12441727B2 (en) 2021-07-07 2025-10-14 Incyte Corporation Tricyclic compounds as inhibitors of KRAS
CA3229855A1 (fr) 2021-08-31 2023-03-09 Incyte Corporation Composes de naphtyridine en tant qu'inhibiteurs de kras
WO2023039464A1 (fr) 2021-09-10 2023-03-16 Gilead Sciences, Inc. Composés de thiénopyrrole
WO2023049697A1 (fr) 2021-09-21 2023-03-30 Incyte Corporation Composés hétéro-tricycliques utilisés en tant qu'inhibiteurs de kras
WO2023056421A1 (fr) 2021-10-01 2023-04-06 Incyte Corporation Inhibiteurs de kras tels que la pyrazoloquinoline
KR20240101561A (ko) 2021-10-14 2024-07-02 인사이트 코포레이션 Kras의 저해제로서의 퀴놀린 화합물

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070232622A1 (en) * 2003-06-20 2007-10-04 Coley Pharmaceutical Gmbh Small molecule toll-like receptor (TLR) antagonists
US20090069314A1 (en) * 2005-02-23 2009-03-12 Coley Pharmaceutical Group, Inc. Hydroxyalkyl Substituted Imidazoquinoline Compounds and Methods
US20100160314A1 (en) * 2006-09-05 2010-06-24 Lipford Grayson B Small Molecule Inhibitors of Toll-Like Receptor 9
US20110136801A1 (en) * 2009-12-03 2011-06-09 Dainippon Sumitomo Pharma Co. Ltd. Novel Compounds

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3854480A (en) 1969-04-01 1974-12-17 Alza Corp Drug-delivery system
US4452775A (en) 1982-12-03 1984-06-05 Syntex (U.S.A.) Inc. Cholesterol matrix delivery system for sustained release of macromolecules
CA1271477A (fr) * 1983-11-18 1990-07-10 John F. Gerster 1h-imidazo[4,5-c]quinoleine-4-amines
US5075109A (en) 1986-10-24 1991-12-24 Southern Research Institute Method of potentiating an immune response
US5133974A (en) 1989-05-05 1992-07-28 Kv Pharmaceutical Company Extended release pharmaceutical formulations
US5407686A (en) 1991-11-27 1995-04-18 Sidmak Laboratories, Inc. Sustained release composition for oral administration of active ingredient
US5491084A (en) 1993-09-10 1996-02-13 The Trustees Of Columbia University In The City Of New York Uses of green-fluorescent protein
US6207646B1 (en) 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US6239116B1 (en) 1994-07-15 2001-05-29 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
DE69535036T3 (de) 1994-07-15 2011-07-07 The University of Iowa Research Foundation, IA Immunomodulatorische oligonukleotide
US5736152A (en) 1995-10-27 1998-04-07 Atrix Laboratories, Inc. Non-polymeric sustained release delivery system
AR006928A1 (es) 1996-05-01 1999-09-29 Pioneer Hi Bred Int Una molecula de adn aislada que codifica una proteina fluorescente verde como marcador rastreable para la transformacion de plantas, un metodo para laproduccion de plantas transgenicas, un vector de expresion, una planta transgenica y celulas de dichas plantas.
AU738513B2 (en) 1997-02-28 2001-09-20 University Of Iowa Research Foundation, The Use of nucleic acids containing unmethylated CpG dinucleotide in the treatment of LPS-associated disorders
WO1998040100A1 (fr) 1997-03-10 1998-09-17 Ottawa Civic Loeb Research Institute UTILISATION D'ACIDES NUCLEIQUES CONTENANT UN DINUCLEOTIDE CpG NON METHYLE EN TANT QU'ADJUVANT
CN1935840A (zh) 1997-05-07 2007-03-28 先灵公司 人Toll样受体蛋白、相关试剂和方法
EP1003531B1 (fr) 1997-05-20 2007-08-22 Ottawa Health Research Institute Procedes de preparation de constructions d'acides nucleiques
ES2284247T3 (es) 1998-04-03 2007-11-01 University Of Iowa Research Foundation Metodos y productos para estimular el sistema inmunitario usando oligonucleotidos y citoquinas inmunoterapeuticos.
EP1077708A1 (fr) 1998-05-06 2001-02-28 University Of Iowa Research Foundation Methodes de prevention et de traitement des parasitoses et maladies associees a l'aide d'oligonucleotides cpg
JP2000119271A (ja) * 1998-08-12 2000-04-25 Hokuriku Seiyaku Co Ltd １ｈ―イミダゾピリジン誘導体
ATE455106T1 (de) 1999-01-22 2010-01-15 Elan Pharm Inc Acyl derivate zur behandlung von krankheiten die in zusammenhang mit vla-4 stehen
DE60029460T3 (de) 1999-09-27 2011-02-10 Coley Pharmaceutical Gmbh Verfahren mittels durch nukleinsäuren induziertes immunostimulatorisches interferon
IL152725A0 (en) 2000-05-25 2003-06-24 Schering Corp Human receptor proteins, related reagents and methods
CN1604795B (zh) 2001-08-17 2010-05-26 科勒制药股份公司 具有提高的活性的组合基序免疫刺激寡肽
US20050004144A1 (en) * 2003-04-14 2005-01-06 Regents Of The University Of California Combined use of IMPDH inhibitors with toll-like receptor agonists
EP1948173B1 (fr) * 2005-11-04 2013-07-17 3M Innovative Properties Company 1h-imidazoquinolines substituees par hydroxy et alcoxy et procedes correspondants
US20100010217A1 (en) * 2006-03-23 2010-01-14 Valiante Nicholas M Methods for the preparation of imidazole-containing compounds
US20080149123A1 (en) * 2006-12-22 2008-06-26 Mckay William D Particulate material dispensing hairbrush with combination bristles
US7943771B2 (en) * 2007-01-24 2011-05-17 Chemagis Ltd. Imiquimod production process
JP5389668B2 (ja) * 2007-01-31 2014-01-15 チョンシー ユー 皮膚浸透率の非常に高い１Ｈ−イミダゾ［４，５−ｃ］キノリン−４−アミン及び関連化合物の正に荷電した水溶性プロドラッグ
EP1972629A1 (fr) 2007-03-23 2008-09-24 Mutabilis SA Nouveaux dérivés d'imidazolo-hétéroaryle ayant des propriétés antibacteriaux
MX2011002264A (es) 2008-09-10 2011-05-23 Kalypsys Inc Inhibidores heterocíclicos de los receptores de histamina para el tratamiento de una enfermedad.
US8728486B2 (en) * 2011-05-18 2014-05-20 University Of Kansas Toll-like receptor-7 and -8 modulatory 1H imidazoquinoline derived compounds

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070232622A1 (en) * 2003-06-20 2007-10-04 Coley Pharmaceutical Gmbh Small molecule toll-like receptor (TLR) antagonists
US20090069314A1 (en) * 2005-02-23 2009-03-12 Coley Pharmaceutical Group, Inc. Hydroxyalkyl Substituted Imidazoquinoline Compounds and Methods
US20100160314A1 (en) * 2006-09-05 2010-06-24 Lipford Grayson B Small Molecule Inhibitors of Toll-Like Receptor 9
US20110136801A1 (en) * 2009-12-03 2011-06-09 Dainippon Sumitomo Pharma Co. Ltd. Novel Compounds

Also Published As

Publication number Publication date
US9873694B2 (en) 2018-01-23
WO2013052550A2 (fr) 2013-04-11
AU2012318694B2 (en) 2016-12-22
IN2014KN00948A (fr) 2015-08-21
IL231957A0 (en) 2014-05-28
CA2850932A1 (fr) 2013-04-11
EP2763677A2 (fr) 2014-08-13
EP2763677A4 (fr) 2015-05-20
JP2014528449A (ja) 2014-10-27
EP2763677B1 (fr) 2020-02-26
AU2012318694A1 (en) 2014-05-22
US20140242121A1 (en) 2014-08-28

Similar Documents

Publication Publication Date Title
WO2013052550A3 (fr) Nouveaux modulateurs du système immunitaire à base d'imidazole quinoline
WO2012021796A3 (fr) Nouveaux dérivés de cyclosporine destinés à la prévention ou au traitement d'une infection virale
WO2013040286A3 (fr) Compositions pharmaceutiques
WO2012009715A3 (fr) Nouveaux dérivés de la cyclosporine destinés à traiter et à prévenir une infection virale
WO2010108074A3 (fr) Inhibiteurs de pi3 kinase
EP4582424A3 (fr) Dérivé de 1,2-naphtoquinone et son procédé de préparation
HK1198697A1 (en) Substituted heteroaromatic pyrazole-containing carboxamide and urea derivatives as vanilloid receptor ligands
WO2011157722A3 (fr) Composition contenant de l'ivabradine solide
CA2881554C (fr) Methodes d'inhibition de la fascine
WO2014195978A3 (fr) Procédé pour la préparation de (3r,4r)-4-méthyl-3-(méthyl-7h-pyrrolo[2,3-d]pyrimidine-4-yl-amino)-ss-oxo-1-pipéridine-propanenitrile et de ses sels
WO2013055684A8 (fr) Citramide de rasagiline
WO2012025944A3 (fr) Sitagliptine, sels et polymorphes de celle-ci
WO2012118308A3 (fr) Composition contenant un dérivé de pyrazole destinée à prévenir et à traiter les maladies cardiovasculaires
WO2011132051A3 (fr) Composés tricycliques en tant qu'inhibiteurs de la phosphodiestérase-10
MX348393B (es) Polimorfo de rifaximina y proceso para la preparacion del mismo.
WO2013093931A3 (fr) Nouveaux promédicaments de médicaments phénoliques
ZA201500362B (en) Novel compound having ability to inhibit 11b-hsd1 enzyme or pharmaceutically acceptable salt thereof, method for producing same, and pharmaceutical composition containing same as active ingredient
WO2013128379A3 (fr) Formes polymorphes cristallines de linagliptine
HK1209105A1 (en) Vegfr3 inhibitors
WO2009145590A3 (fr) Composés de phényl-pipérazine, composition pharmaceutique les comprenant, et utilisation associée
WO2012118309A3 (fr) Dérivés de pyrazole, procédé pour les préparer et composition les contenant destinée à prévenir et à traiter l'ostéoporose
PH12013501055A1 (en) Quinoline derivative compound, method for preparing same, and pharmaceutical composition containing same
PH12013501054A1 (en) Quinoline derivative compound, method for preparing same, and pharmaceutical composition containing same
WO2013028615A8 (fr) Nouveaux dérivés de la cyclosporine destinés à traiter et à prévenir des infections virales
SI3882244T1 (sl) Spojina, farmacevtsko sprejemljiva sol ali optični izomer le-te, postopek za njeno pripravo in farmacevtski sestavek za preprečevanje ali zdravljenje virusnih bolezni, ki jo vsebuje kot učinkovino

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 12837804

Country of ref document: EP

Kind code of ref document: A2

ENP Entry into the national phase

Ref document number: 2850932

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 14349254

Country of ref document: US

ENP Entry into the national phase

Ref document number: 2014534658

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 231957

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 2012837804

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2012318694

Country of ref document: AU

Date of ref document: 20121003

Kind code of ref document: A